1,4-disubstituted piperazine ligands for neurotransmitter receptors
    2.
    发明授权
    1,4-disubstituted piperazine ligands for neurotransmitter receptors 有权
    用于神经递质受体的1,4-二取代哌嗪配体

    公开(公告)号:US07030122B2

    公开(公告)日:2006-04-18

    申请号:US10401106

    申请日:2003-03-27

    摘要: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including serotonin receptors and dopamine receptors. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, and senile dementia.

    摘要翻译: 本发明的一个方面涉及新的杂环化合物。 本发明的第二方面涉及新型杂环化合物作为各种细胞受体(包括血清素受体和多巴胺受体)的配体的用途。 本发明的化合物可用于治疗多种疾病,疾病,其包括但不限于成瘾,焦虑,抑郁,性功能障碍,高血压,偏头痛,阿尔茨海默病,肥胖,呕吐,精神病, 止痛,精神分裂症,帕金森病,不宁腿综合征,睡眠障碍,注意缺陷多动障碍,肠易激综合征,早泄,月经性烦躁综合症,尿失禁,炎性疼痛,神经性疼痛,莱氏阴道炎,威尔逊病,图雷特综合征, 精神障碍,中风和老年痴呆。

    LIGANDS FOR IMAGING CARDIAC INNERVATION
    6.
    发明申请
    LIGANDS FOR IMAGING CARDIAC INNERVATION 有权
    用于成像心脏感染的配对

    公开(公告)号:US20100221182A1

    公开(公告)日:2010-09-02

    申请号:US12448575

    申请日:2007-12-21

    摘要: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

    摘要翻译: 公开了用于心脏神经支配成像的核医学应用(PET成像)中用作成像剂的新型化合物。 这些基于PET的放射性示踪剂可能表现出增加的稳定性,减少NE释放(从而减少副作用),改进的定量数据,和/或对先前的放射性示踪剂对VMAT的高亲和力。 还提供了使用化合物成像心脏神经支配的方法。 在某些情况下,化合物通过在各种位置上衍生化某些化合物而形成:芳基,烷基,酮基,苄基,β-烷基醚,γ-丙基烷基醚和β-丙基烷基醚。 或者或另外,将甲基a加入到胺中,和/或儿茶酚官能团被消除或掩蔽,作为使这些化合物更稳定的方式。